ABL1 D363G

CI-VAR-00000484Explore in graph →CIViC 4637

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
BCR::ABL1 Fusion AND ABL1 D363G	Dasatinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID4692 Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the D363G secondary variant in 2/10 bacterial clones generated … (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 D363G	Imatinib	Predictive	C	Supports Resistance	1	accepted	EID7820 One chronic myeloid leukemia patient in chronic phase had a partial best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA revealed the BCR-A… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.